The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...

For payers, the case for patient engagement in CKD is compelling. It improves outcomes, reduces costs, supports quality metrics and star ratings, and strengthens member satisfaction. But it doesn’t ...

Exposure to endocrine-disrupting bisphenol chemicals—including bisphenol A (BPA), bisphenol S (BPS), and bisphenol F (BPF)—was associated with more than 127 million cases of obesity, type 2 diabetes ...

Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over ...

Panelists discuss how outdated coverage models lag behind oncology innovation, calling for dynamic policies that reflect ...

Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with ...

Panelists discuss how increasing utilization management oversight affects physician autonomy and the shared decision-making ...

Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to ...

Panelists discuss how utilization management policies can delay oncology care and call for reforms that better align ...

Panelists discuss how payers should interpret black box warnings with clinical context to prevent unnecessary restrictions on ...

Panelists discuss how the Inflation Reduction Act (IRA) introduces landmark changes to drug pricing through its negotiation ...

Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and ...